AccessibilityHelp

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Most Active Stocks Daily Stock Gainers Daily Stock Losers

George Budwell, PhD

TMFGBudwell

George Budwell, PhD, is a contributing Motley Fool biotechnology and technology analyst covering disruptive innovators in healthcare, defense, and artificial intelligence. He also writes on portfolio theory, dividend stocks, and value investing. Prior to The Motley Fool, George was a freelance medical and science writer and a consultant for several life sciences hedge funds. Earlier in his career, he was an evolutionary biologist and completed postdoctoral fellowships at Kyoto University and Illinois State University. He holds a doctorate in evolutionary biology from Tulane University and a bachelor’s degree from Loyola University.

Articles by George Budwell, PhD — Page 150

1 Amazing Chart Shows Why Gilead Sciences, Inc.'s Stock Still Belongs in Your Portfolio

Jan 8, 2015 by George Budwell, PhD

1 Amazing Chart Shows Why Gilead Sciences, Inc.'s Stock Still Belongs in Your Portfolio

Gilead Sciences saw its shares drop by close to 20% after its chief competitor, AbbVie, delivered a major blow to its hepatitis C franchise. A single chart, though, shows why selling this top biotech stock is probably a huge mistake.

Does Pfizer Inc. Stock Offer a Market-Crushing Opportunity in 2015?

Jan 6, 2015 by George Budwell, PhD

Does Pfizer Inc. Stock Offer a Market-Crushing Opportunity in 2015?

Pfizer's stock has languished for the better part of a decade now, failing to benefit from the broader bull market. With several key events on the horizon, this trend could change in a big way. Here's what investors need to know.

Growth Stocks 2015: 3 Companies With Room to Run

Jan 4, 2015 by George Budwell, PhD

Growth Stocks 2015: 3 Companies With Room to Run

AbbVie, Celgene, and Gilead Sciences are three growth stocks with room to run in 2015 and beyond. Here's why.

Does This Dividend Stock Belong in Your Portfolio in 2015?

Jan 4, 2015 by George Budwell, PhD

Does This Dividend Stock Belong in Your Portfolio in 2015?

Teva Pharmaceutical Industries is a favorite name among income investors. With steep headwinds facing the company in 2015, though, its dividend might be at risk. Here's what investors need to know.

Is GlaxoSmithKline plc's Monster Dividend Worth the Risk?

Dec 30, 2014 by George Budwell, PhD

Is GlaxoSmithKline plc's Monster Dividend Worth the Risk?

GlaxoSmithKline has had a rotten 2014, leading to a dramatic downturn in its share price. Can this high-yielding dividend stock rebound in 2015?

Billionaires Are Gobbling Up These Stocks Right Now

Dec 30, 2014 by George Budwell, PhD

Billionaires Are Gobbling Up These Stocks Right Now

Billionaires took out huge positions in AbbVie, Celladon Corp., and Kite Pharma in the third quarter. Should you follow in their giant footsteps?

3 Stocks Poised for Eye-Popping Gains in 2015

Dec 27, 2014 by George Budwell, PhD

3 Stocks Poised for Eye-Popping Gains in 2015

Gilead Sciences, Orexigen Therapeutics, and Prothena Corp. are all poised to have a huge 2015. Here's what investors need to know.

3 Drugmakers Facing a Pivotal 2015

Dec 22, 2014 by George Budwell, PhD

3 Drugmakers Facing a Pivotal 2015

Isis Pharmaceuticals, PTC Therapeutics, and GW Pharmaceuticals all expect 2015 to be a pivotal year in their drive toward becoming commercially viable entities. Should investors jump in before the catalysts spark?

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Dec 22, 2014 by George Budwell, PhD

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?

Why Is George Soros Buying This Beaten Down Biotech Stock?

Dec 21, 2014 by George Budwell, PhD

Why Is George Soros Buying This Beaten Down Biotech Stock?

Soros Fund Management opened a position in the struggling biotech Aegerion Pharmaceuticals in the third quarter, even while the drugmaker's revenue estimates continued to plummet. Should retail investors follow his lead into this beaten down biotech?

Does George Soros Think Biotech's Bull Run Is Finally Coming to an End?

Dec 15, 2014 by George Budwell, PhD

Does George Soros Think Biotech's Bull Run Is Finally Coming to an End?

The Soros Fund Managment sold off a number of biotechs in the third quarter. Do the actions of this closely watched fund signal that the industry's bull run is finally winding down?

3 Stocks That Might Slash Their Dividends in 2015

Dec 14, 2014 by George Budwell, PhD

3 Stocks That Might Slash Their Dividends in 2015

These three companies all offer sector-beating dividend yields. But with each facing serious headwinds, can they maintain these huge yields next year?

Should Celgene Corporation Pay a Dividend?

Dec 11, 2014 by George Budwell, PhD

Should Celgene Corporation Pay a Dividend?

Celgene Corp. has become one of the world's fastest growing biotechs, with the cash flows to match. Is it time for management to consider a dividend? Or could the company be waiting to use its cash on something else?

Is It Time to Buy This Growth Stock?

Dec 8, 2014 by George Budwell, PhD

Is It Time to Buy This Growth Stock?

Specialty and generic drugmaker Actavis has been going through a rapid growth spurt, spurred by its numerous acquisitions. After completing a mega merger with Botox-maker Allergan, can the uptrend continue?

Time to Buy This Dip in Gilead Sciences, Inc. Stock?

Dec 8, 2014 by George Budwell, PhD

Time to Buy This Dip in Gilead Sciences, Inc. Stock?

Shares of Gilead Sciences have slipped over the last month. Is now the time to buy this top biotech?

George Soros Is Dumping These 3 Dividend Stocks: Should You?

Dec 7, 2014 by George Budwell, PhD

George Soros Is Dumping These 3 Dividend Stocks: Should You?

Billionaire and hedge fund guru George Soros sold Eli Lilly, Johnson & Johnson, and Teva Pharmaceutical in the third-quarter. Should average investors do the same?

Is Exelixis, Inc. Stock Doomed?

Dec 2, 2014 by George Budwell, PhD

Is Exelixis, Inc. Stock Doomed?

Small-cap biotech Exelixis has fallen hard in 2014. Could the stock rebound next year, or will it drop even further?

3 Biotech Stocks With Jaw-Dropping Growth Potential in 2015

Nov 29, 2014 by George Budwell, PhD

3 Biotech Stocks With Jaw-Dropping Growth Potential in 2015

Biotech stocks have been crushing the broader markets in recent years. Here are three biotech companies poised to continue this trend in 2015.

Should Gilead Sciences, Inc. Pay a Dividend?

Nov 26, 2014 by George Budwell, PhD

Should Gilead Sciences, Inc. Pay a Dividend?

Shares of Gilead Sciences have skyrocketed over the past two years, propelling the company into the upper echelons of the healthcare sector in terms of market cap. With all of its new peer group offering a dividend, should Gilead follow suit?

George Soros Just Bought These 3 Stocks: Should You?

Nov 23, 2014 by George Budwell, PhD

George Soros Just Bought These 3 Stocks: Should You?

Controversial billionaire George Soros purchased large stakes in AbbVie, Actavis plc, and Valeant Pharmaceuticals in the third-quarter. Should you follow in his footsteps?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services